This is supported by recent findings in breast cancer cell lines that different synthetic progestins cause many of the same cellular outcomes when signaling through the classical or nuclear progesterone receptor (PGR), but have seemingly distinct PGRMC1-dependent actions [14,15]. The gene discussed is PGR; the disease is breast carcinoma.